BioCentury | Nov 4, 2020
Deals

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

...with co-founder Paul Sekhri, president and CEO of eGenesis Inc....
...NYSE:NVS; SIX:NOVN) himself  — is remaining at eGenesis. ...
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

...hepatitis D (see “Hepatitis D Draft Guidance Outlines Surrogate Endpoints” ). eGenesis consolidates supply chain eGenesis Inc....
...GS-6034) Sarasar, lonafarnib (mk-6336, sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Gilead Sciences Inc. Galapagos N.V. Merck & Co. Inc. Eiger BioPharmaceuticals Inc. eGenesis Inc. ICB...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...Sekhri and Sandy Zweifach as venture partners. Sekhri is president and CEO of xenotransplantation company eGenesis Inc....
BioCentury | Nov 14, 2019
Company News

Months after investment, Bayer strikes option deal with Dewpoint in CV, women’s health

...company eGenesis Inc., oncology play Pyxis Inc. and pluripotent stem cell company Century Therapeutics LLC (see “eGenesis...
BioCentury | Nov 8, 2019
Financial News

eGenesis pushes to bring pig organ transplants to humans with $100M series B

...as did existing investors including Arch Venture Partners, Biomatics Capital, Alta Partners and Khosla Ventures. eGenesis Inc....
...told BioCentury. Now was the right time to enter the xenotransplantation space, Eckhardt said, because eGenesis’...
...inactivated clones (see “eGenesis Strides Toward Safe Pig Organ Transplants” ). Along with eliminating PERV, eGenesis...
BioCentury | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

...antiviral company’s COO. Sapir was president and CEO at Dova Pharmaceuticals Inc. (NASDAQ:DOVA). Xenotransplantation company eGenesis Inc....
...analysis company MDClone Ltd. (Beersheba, Israel), both of which he co-founded. BioCentury Staff Agios Pharmaceuticals Inc. Biophytis S.A. Celsius Therapeutics eGenesis Inc. EyePoint...
BioCentury | Jan 17, 2019
Company News

Management tracks: eGenesis names Sekhri CEO

...Xenotransplantation company eGenesis Inc. (Cambridge, Mass.) hired Paul Sekhri as president and CEO. He succeeds interim CEO...
BioCentury | Dec 14, 2018
Company News

BayHelix launches gene-editing task force

...Chinese CRO Fountain Medical Development Ltd. (Beijing, China), and Luhan Yang, co-founder and CSO of eGenesis Inc....
BioCentury | Dec 13, 2018
Politics & Policy

BayHelix launches gene-editing task force

...Chinese CRO Fountain Medical Development Ltd. (Beijing, China), and Luhan Yang, co-founder and CSO of eGenesis Inc....
BioCentury | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

...Corp. (NASDAQ:CELG), where he was VP of global marketing for inflammation and immunology. Xenotransplantation company eGenesis Inc....
Items per page:
1 - 10 of 22
BioCentury | Nov 4, 2020
Deals

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

...with co-founder Paul Sekhri, president and CEO of eGenesis Inc....
...NYSE:NVS; SIX:NOVN) himself  — is remaining at eGenesis. ...
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

...hepatitis D (see “Hepatitis D Draft Guidance Outlines Surrogate Endpoints” ). eGenesis consolidates supply chain eGenesis Inc....
...GS-6034) Sarasar, lonafarnib (mk-6336, sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Gilead Sciences Inc. Galapagos N.V. Merck & Co. Inc. Eiger BioPharmaceuticals Inc. eGenesis Inc. ICB...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...Sekhri and Sandy Zweifach as venture partners. Sekhri is president and CEO of xenotransplantation company eGenesis Inc....
BioCentury | Nov 14, 2019
Company News

Months after investment, Bayer strikes option deal with Dewpoint in CV, women’s health

...company eGenesis Inc., oncology play Pyxis Inc. and pluripotent stem cell company Century Therapeutics LLC (see “eGenesis...
BioCentury | Nov 8, 2019
Financial News

eGenesis pushes to bring pig organ transplants to humans with $100M series B

...as did existing investors including Arch Venture Partners, Biomatics Capital, Alta Partners and Khosla Ventures. eGenesis Inc....
...told BioCentury. Now was the right time to enter the xenotransplantation space, Eckhardt said, because eGenesis’...
...inactivated clones (see “eGenesis Strides Toward Safe Pig Organ Transplants” ). Along with eliminating PERV, eGenesis...
BioCentury | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

...antiviral company’s COO. Sapir was president and CEO at Dova Pharmaceuticals Inc. (NASDAQ:DOVA). Xenotransplantation company eGenesis Inc....
...analysis company MDClone Ltd. (Beersheba, Israel), both of which he co-founded. BioCentury Staff Agios Pharmaceuticals Inc. Biophytis S.A. Celsius Therapeutics eGenesis Inc. EyePoint...
BioCentury | Jan 17, 2019
Company News

Management tracks: eGenesis names Sekhri CEO

...Xenotransplantation company eGenesis Inc. (Cambridge, Mass.) hired Paul Sekhri as president and CEO. He succeeds interim CEO...
BioCentury | Dec 14, 2018
Company News

BayHelix launches gene-editing task force

...Chinese CRO Fountain Medical Development Ltd. (Beijing, China), and Luhan Yang, co-founder and CSO of eGenesis Inc....
BioCentury | Dec 13, 2018
Politics & Policy

BayHelix launches gene-editing task force

...Chinese CRO Fountain Medical Development Ltd. (Beijing, China), and Luhan Yang, co-founder and CSO of eGenesis Inc....
BioCentury | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

...Corp. (NASDAQ:CELG), where he was VP of global marketing for inflammation and immunology. Xenotransplantation company eGenesis Inc....
Items per page:
1 - 10 of 22